Hamostaseologie最新文献

筛选
英文 中文
Intensive Care Treatment of Pulmonary Embolism: An Update Based on the Revised AWMF S2k Guideline. 肺栓塞的重症监护治疗:基于修订版 AWMF S2k 指南的更新。
IF 3.2 4区 医学
Hamostaseologie Pub Date : 2024-04-01 Epub Date: 2024-03-18 DOI: 10.1055/a-2237-7428
Uwe Janssens
{"title":"Intensive Care Treatment of Pulmonary Embolism: An Update Based on the Revised AWMF S2k Guideline.","authors":"Uwe Janssens","doi":"10.1055/a-2237-7428","DOIUrl":"10.1055/a-2237-7428","url":null,"abstract":"<p><p>Acute pulmonary embolism (PE) remains a significant cause of morbidity and requires prompt diagnosis and management. The prognosis of affected patients depends on the clinical severity. Therefore, risk stratification is imperative for therapeutic decision-making. Patients with high-risk PE need intensive care. These include patients who have successfully survived resuscitation, with obstructive shock or persistent haemodynamic instability. Bedside diagnostics by means of sonographic procedures are of outstanding importance in this high-risk population. In addition to the treatment of hypoxaemia with noninvasive and invasive techniques, the focus is on drug-based haemodynamic stabilisation and usually requires the elimination or reduction of pulmonary vascular thrombotic obstruction by thrombolysis. In the event of a contraindication to thrombolysis or failure of thrombolysis, various catheter-based procedures for thrombus extraction and local thrombolysis are available today and represent an increasing alternative to surgical embolectomy. Mechanical circulatory support systems can bridge the gap between circulatory arrest or refractory shock and definitive stabilisation but are reserved for centres with the appropriate expertise. Therapeutic strategies for patients with intermediate- to high-risk PE in terms of reduced-dose thrombolytic therapy or catheter-based procedures need to be further evaluated in prospective clinical trials.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"119-127"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aktueller Bericht der BDDH über die aktuellen gesundheitspolitischen Entwicklungen mit politischer Einordnung. BDDH 关于当前卫生政策发展的最新报告,并进行了政治分类。
IF 3.2 4区 医学
Hamostaseologie Pub Date : 2024-04-01 Epub Date: 2024-04-30 DOI: 10.1055/a-2239-5959
Jürgen Koscielny, Günther Kappert, Christoph Sucker
{"title":"Aktueller Bericht der BDDH über die aktuellen gesundheitspolitischen Entwicklungen mit politischer Einordnung.","authors":"Jürgen Koscielny, Günther Kappert, Christoph Sucker","doi":"10.1055/a-2239-5959","DOIUrl":"10.1055/a-2239-5959","url":null,"abstract":"","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"44 2","pages":"156-157"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum: Aktueller Bericht der BDDH über die aktuellen gesundheitspolitischen Entwicklungen mit politischer Einordnung. 勘误:目前 BDDH 关于当前卫生政策发展的报告,含政治分类。
IF 3.2 4区 医学
Hamostaseologie Pub Date : 2024-04-01 Epub Date: 2024-05-21 DOI: 10.1055/s-0044-1787122
Jürgen Koscielny, Günther Kappert, Christoph Sucker
{"title":"Erratum: Aktueller Bericht der BDDH über die aktuellen gesundheitspolitischen Entwicklungen mit politischer Einordnung.","authors":"Jürgen Koscielny, Günther Kappert, Christoph Sucker","doi":"10.1055/s-0044-1787122","DOIUrl":"https://doi.org/10.1055/s-0044-1787122","url":null,"abstract":"","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":"44 2","pages":"e1"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141076872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis and Therapy of Visceral Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline. 内脏静脉血栓的诊断和治疗:基于修订的AWMF S2k指南的更新。
IF 3.2 4区 医学
Hamostaseologie Pub Date : 2024-04-01 Epub Date: 2023-11-22 DOI: 10.1055/a-2178-6670
Katja S Mühlberg
{"title":"Diagnosis and Therapy of Visceral Vein Thrombosis: An Update Based on the Revised AWMF S2k Guideline.","authors":"Katja S Mühlberg","doi":"10.1055/a-2178-6670","DOIUrl":"10.1055/a-2178-6670","url":null,"abstract":"<p><p>Splanchnic or visceral vein thromboses (VVTs) are atypical thrombotic entities and include thrombosis of the portal vein, hepatic veins (Budd-Chiari syndrome), mesenteric veins, and splenic vein. All VVTs have in common high 30-day mortality up to 20% and it seems to be difficult to diagnose VVT early because of their rarity and their wide spectrum of unspecific symptoms. VVTs are often associated with myeloproliferative neoplasia, thrombophilia, and liver cirrhosis. VVT is primarily diagnosed by sonography and/or computed tomography. In contrast to venous thromboembolism, D-dimer testing is neither established nor helpful. Anticoagulation is the first-line therapy in patients with stable circulation and no evidence of organ complications. Anticoagulation improves significantly recanalization rates and stops the progress of thrombosis. Low-molecular-weight heparin, vitamin K antagonists, as well as direct-acting oral anticoagulants are possible anticoagulants, but it is noteworthy to be aware that all recommendations supporting the off-label use of anticoagulants are based on poor evidence and consist predominantly of case series, observational studies, or studies with small case numbers. When choosing a suitable anticoagulation, the individual risk of bleeding and thrombosis must be weighted very carefully. In cases of bleeding, bowel infarction, or other complications, the optimal therapy should be determined on a case-by-case basis by an experienced multidisciplinary team involving a surgeon. Besides anticoagulation, there are therapeutic options including thrombectomy, balloon angioplasty, stenting, transjugular placement of an intrahepatic portosystemic shunt, liver transplantation, and ischemic bowel resection. This article gives an overview of current diagnostic and therapeutic strategies.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"135-142"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138296607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Post-Pulmonary Embolism Syndrome: An Update Based on the Revised AWMF-S2k Guideline. 肺栓塞后综合征:基于修订版 AWMF-S2k 指南的更新。
IF 3.2 4区 医学
Hamostaseologie Pub Date : 2024-04-01 Epub Date: 2024-03-26 DOI: 10.1055/a-2229-4190
F Joachim Meyer, Christian Opitz
{"title":"Post-Pulmonary Embolism Syndrome: An Update Based on the Revised AWMF-S2k Guideline.","authors":"F Joachim Meyer, Christian Opitz","doi":"10.1055/a-2229-4190","DOIUrl":"10.1055/a-2229-4190","url":null,"abstract":"<p><p>In survivors of acute pulmonary embolism (PE), the post-PE syndrome (PPES) may occur. In PPES, patients typically present with persisting or progressive dyspnea on exertion despite 3 months of therapeutic anticoagulation. Therefore, a structured follow-up is warranted to identify patients with chronic thromboembolic pulmonary disease (CTEPD) with normal pulmonary pressure or chronic thromboembolic pulmonary hypertension (CTEPH). Both are currently understood as a dual vasculopathy, that is, secondary arterio- and arteriolopathy, affecting the large and medium-sized pulmonary arteries as well as the peripheral vessels (diameter < 50 µm). The follow-up algorithm after acute PE commences with identification of clinical symptoms and risk factors for CTEPH. If indicated, a stepwise performance of echocardiography, ventilation-perfusion scan (or alternative imaging), N-terminal prohormone of brain natriuretic peptide (NT-proBNP) level, cardiopulmonary exercise testing, and pulmonary artery catheterization with angiography should follow. CTEPH patients should be treated in a multidisciplinary center with adequate experience in the complex therapeutic options, comprising pulmonary endarterectomy, balloon pulmonary angioplasty, and pharmacological interventions.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"128-134"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140295419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer-Associated Venous Thromboembolism-Diagnostic and Therapeutic Considerations: An Update Based on the Revised AWMF S2k Guideline. 癌症相关静脉血栓栓塞——诊断和治疗考虑:基于修订的AWMF S2k指南的更新
IF 3.2 4区 医学
Hamostaseologie Pub Date : 2024-04-01 Epub Date: 2023-11-22 DOI: 10.1055/a-2178-6508
Hanno Riess, Jan Beyer-Westendorf, Uwe Pelzer, Robert Klamroth, Birgit Linnemann
{"title":"Cancer-Associated Venous Thromboembolism-Diagnostic and Therapeutic Considerations: An Update Based on the Revised AWMF S2k Guideline.","authors":"Hanno Riess, Jan Beyer-Westendorf, Uwe Pelzer, Robert Klamroth, Birgit Linnemann","doi":"10.1055/a-2178-6508","DOIUrl":"10.1055/a-2178-6508","url":null,"abstract":"<p><p>Patients with cancer are prone to develop venous thromboembolism (VTE) with negative impact on quality of life, morbidity, and mortality. Treatment of established VTE is often complex in patients with cancer. Treatment of cancer-associated VTE (CAT) basically comprises initial and maintenance treatment, for 3 to 6 months, secondary preventions, and treatment in special situations. Therapeutic anticoagulation is the treatment of choice in CAT. In addition to the efficacy and safety of low-molecular-weight heparin (LMWH) that had been recommended for decades, direct oral anti-factor Xa inhibitors, a subgroup of direct oral anticoagulants (DOACs), demonstrated their advantages along with the accompanying concerns in several randomized controlled treatment trials of CAT. The latest guidelines, such as the German AWMF-S2k Guideline \"Diagnostics and Therapy of Venous Thrombosis and Pulmonary Embolism,\" agree with each other on most aspects with respect to the treatment of CAT. Encompassing recent clinical studies, and meta-analyses, as well as the focus on some special management aspects of CAT, the objective of this review is to present a current overview and recommendations for the treatment of CAT.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":"143-149"},"PeriodicalIF":3.2,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138296606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report. 使用 Vonicog Alpha 和获得性 von Willebrand 综合征,一种新方法:病例报告。
IF 3.2 4区 医学
Hamostaseologie Pub Date : 2024-03-22 DOI: 10.1055/a-2266-7984
Adeline Blandinières, Sophie Combe, Noémie Chanson, Olivier Lambotte, Cécile Lavenu-Bombled
{"title":"Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report.","authors":"Adeline Blandinières, Sophie Combe, Noémie Chanson, Olivier Lambotte, Cécile Lavenu-Bombled","doi":"10.1055/a-2266-7984","DOIUrl":"https://doi.org/10.1055/a-2266-7984","url":null,"abstract":"<p><p>Therapeutic management of acquired von Willebrand syndrome (AVWS) can be challenging, particularly in cases of AVWS associated with monoclonal IgM such as Waldenström macroglobulinemia (WM) where several therapeutic options may be ineffective. Here, we describe the case of an 88-year-old patient who developed AVWS during follow-up for WM. The presence of a severe bleeding symptomatology not controlled by several therapies (plasma-derived von Willebrand factor, plasmapheresis) led us to introduce a supplementation with recombinant von Willebrand factor, vonicog α (Veyvondi, Takeda, Japan), starting at a dose of 50 IU/kg/d. This supplementation allowed clinical (no further bleeding) and biological (hemoglobin level, von Willebrand factor parameters) improvements. Because of the persistence of bleeding risk factors, the treatment was maintained at a prophylactic dose (20 UI/kg three times a week), without recurrence of bleeding events for a period of 9 months.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140190436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Perspectives on Thrombopoietin Receptor Agonists Applications. 血小板生成素受体激动剂应用的新视角。
IF 3.2 4区 医学
Hamostaseologie Pub Date : 2024-03-18 DOI: 10.1055/a-2250-9369
Christos Stafylidis, Dimitra Vlachopoulou, Stavroula Syriopoulou, Sevastianos Chatzidavid, Nora-Athina Viniou
{"title":"Novel Perspectives on Thrombopoietin Receptor Agonists Applications.","authors":"Christos Stafylidis, Dimitra Vlachopoulou, Stavroula Syriopoulou, Sevastianos Chatzidavid, Nora-Athina Viniou","doi":"10.1055/a-2250-9369","DOIUrl":"https://doi.org/10.1055/a-2250-9369","url":null,"abstract":"<p><p>Second-generation thrombopoietin receptor agonists (TPO-RAs), romiplostim, eltrombopag, and avatrombopag, have been proved to be significant stimulators of megakaryopoiesis and, in the last decade, they have been incorporated in the treatment options against refractory immune thrombocytopenia in children and adults that do not respond to conventional therapy. Additionally, given their beneficial impact on hematopoiesis, they have successfully been applied in cases of non-immune thrombocytopenia, such as aplastic anemia, HCV-related thrombocytopenia, chronic liver disease, and most recently acute radiation syndrome. During the past years, a wide variety of clinical studies have been performed, in regard to the use of TPO-RAs in various thrombocytopenic settings, such as malignant hematology and hematopoietic stem cell transplantation, hereditary thrombocytopenias, and chemotherapy-treated patients with solid organ tumors. Although data indicate that TPO-RAs may be an effective and safe option for managing disease- or treatment-related thrombocytopenia in these patients, further research is needed to determine their efficacy and safety in these settings. Furthermore, recent studies have highlighted novel properties of TPO-RAs that render them as potential treatment candidates for reducing tumor burden or fighting infections. Herein, we discuss the potential novel applications of TPO-RAs and focus on data regarding their efficacy and safety in these contexts.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thrombosis in Acute Promyelocytic Leukemia: The Current Understanding. 急性早幼粒细胞白血病的血栓形成:目前的认识。
IF 3.2 4区 医学
Hamostaseologie Pub Date : 2024-03-11 DOI: 10.1055/a-2238-4782
Nikica Sabljic, Mirjana Mitrovic, Nikola Pantic, Jecko Thachil
{"title":"Thrombosis in Acute Promyelocytic Leukemia: The Current Understanding.","authors":"Nikica Sabljic, Mirjana Mitrovic, Nikola Pantic, Jecko Thachil","doi":"10.1055/a-2238-4782","DOIUrl":"https://doi.org/10.1055/a-2238-4782","url":null,"abstract":"<p><p>Despite enormous improvement in the management of patients with acute promyelocytic leukemia (APL), the distinctive coagulopathy observed at presentation in affected patients is often life-threatening. While hemorrhagic manifestations are well known and described in this setting, APL-related thromboses are underappreciated. Data regarding this complication are scarce showing variable incidence. Furthermore, risk factors for thrombosis are inconsistent and unreliable; so, differentiation of increased risk of hemorrhage from an increased thrombotic risk is quite difficult in the absence of adequate predictive scores. Besides, prophylactic use of anticoagulants and recombinant thrombomodulin are a matter of ongoing debate. Also, due to the common feature of thrombocytopenia and other hemorrhagic risks, patients with APL are excluded from trials analyzing anticoagulant prophylaxis in cancers; so, data from prospective trials are lacking. A detailed analysis of thrombotic risks in APL with the development of a reliable risk stratification model is needed to further improve the care of APL patients.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantifying Residual Rivaroxaban Plasma Concentration after Antagonization with Andexanet Alfa: A Difficult Task in Routine Clinical Practice. 量化安达沙奈α拮抗后残留的利伐沙班血浆浓度:常规临床实践中的一项艰巨任务。
IF 3.2 4区 医学
Hamostaseologie Pub Date : 2024-03-11 DOI: 10.1055/a-2266-8021
Alexander Mair, Gilles Huber, Jan-Dirk Studt, Donat R Spahn, Alexander Kaserer
{"title":"Quantifying Residual Rivaroxaban Plasma Concentration after Antagonization with Andexanet Alfa: A Difficult Task in Routine Clinical Practice.","authors":"Alexander Mair, Gilles Huber, Jan-Dirk Studt, Donat R Spahn, Alexander Kaserer","doi":"10.1055/a-2266-8021","DOIUrl":"https://doi.org/10.1055/a-2266-8021","url":null,"abstract":"<p><p>We describe the case of a 38-year-old man with a history of chronic portal vein thrombosis who presented with abdominal pain after a transjugular intrahepatic portosystemic shunt procedure. Under anticoagulation therapy with rivaroxaban, he experienced active splenic bleeding, leading to hemodynamic instability. Emergency interventions, including andexanet alfa and nanoparticle administration, successfully stopped the bleeding. However, routine tests showed persistently high rivaroxaban levels despite reversal with andexanet alfa. This case report shows that next to standard anti-Xa activity assay, high-performance liquid chromatography is as well unreliable in this regard. In contrast, viscoelastic tests might better serve as indicators of the efficacy of the reversal. The availability of modified anti-Xa tests is urgently needed, to monitor the effects of andexanet alfa reversal.</p>","PeriodicalId":55074,"journal":{"name":"Hamostaseologie","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140102902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信